Business Context and Reporting Period
This Form 8-K filing by Spero Therapeutics, Inc. (a Delaware corporation) reports corporate governance changes effective March 19, 2019. The Company is an emerging growth company focused on the biopharmaceutical sector.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to the appointment of a new director and board size adjustment.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: Cynthia Smith was appointed as a Class I Director, effective March 19, 2019. Her term extends until the 2021 annual meeting of stockholders.
- Committee Assignments: Specific committee assignments for Ms. Smith have not yet been determined.
Management Commentary and Compensation
The Board determined Ms. Smith is an independent director under Nasdaq standards. She brings over 20 years of healthcare leadership experience, including roles as Chief Commercial Officer at ZS Pharma and senior positions at Merck & Co. and the White House Office of Management and Budget. She currently serves on the boards of Dicerna Pharmaceuticals, Inc. and Akebia Therapeutics, Inc.
Ms. Smith will receive standard non-employee director compensation pro-rated for the year, along with a standard indemnification agreement. No material transactions or family relations with existing directors were disclosed.
Investor Verification Checklist
- Verify the pro-rated compensation amount for Ms. Smith in the Company's Non-Employee Director Compensation Policy (referenced in Form S-1).
- Monitor future filings for Ms. Smith's specific Board committee assignments.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.